- Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
- Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
- Context Therapeutics Announces $100 Million Private Placement
- Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
- Context Therapeutics Reports Full Year 2023 Operating and Financial Results
- Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
- Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
- Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
- Context Therapeutics to Participate in Two August 2023 Investor Conferences
More ▼
Key statistics
As of last trade Context Therapeutics Inc (CNTX:NAQ) traded at 1.82, -18.75% below its 52-week high of 2.24, set on Jun 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.84 |
---|---|
High | 1.84 |
Low | 1.80 |
Bid | 1.81 |
Offer | 1.84 |
Previous close | 1.84 |
Average volume | 945.77k |
---|---|
Shares outstanding | 75.00m |
Free float | 72.91m |
P/E (TTM) | -- |
Market cap | 138.00m USD |
EPS (TTM) | -1.34 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 14:57 BST.
More ▼